1. Academic Validation
  2. Pharmacokinetic Modeling of ( R)-[11C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

Pharmacokinetic Modeling of ( R)-[11C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

  • Mol Pharm. 2021 Jan 4;18(1):416-428. doi: 10.1021/acs.molpharmaceut.0c01014.
Lara García-Varela 1 David Vállez García 1 Takeharu Kakiuchi 2 Hiroyuki Ohba 2 Shingo Nishiyama 2 Tetsuro Tago 3 Philip H Elsinga 1 Hideo Tsukada 2 Nicola A Colabufo 4 5 Rudi A J O Dierckx 1 Aren van Waarde 1 Jun Toyohara 3 Ronald Boellaard 1 Gert Luurtsema 1
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, Groningen 9713 GZ, The Netherlands.
  • 2 Central Research Laboratory, Hamamatsu Photonics KK, 5000 Hirakuchi, Hamakita, Hamamatsu 434-8601, Shizuoka, Japan.
  • 3 Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan.
  • 4 Department of Pharmacy, University of Bari Aldo Moro, Bari 70125, Italy.
  • 5 Biofordrug, Spin-off Università degli Studi di Bari "A. Moro", via Dante 99, Triggiano, Bari 70019, Italy.
Abstract

(R)-[11C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood-brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[11C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[11C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[11C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[11C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[11C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[11C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (VT) and the efflux constant k2 estimations were affected by the evaluated scan durations, whereas the influx constant K1 estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain VT increased significantly up to 208% (p < 0.001) and K1 up to 159% (p < 0.001) compared with baseline scans. The k2 values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K1, calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates.

Keywords

ABC transporters; P-gp tracers; brain imaging; efflux transporters; kinetics; rhesus monkeys.

Figures
Products